News about Drug Discovery & Development

Haisco Signs Exclusive Deal with AbbVie to Develop Novel Pain Therapies

Haisco partners with AbbVie to develop novel pain therapies, with multiple compounds in preclinical to Phase 1 stages targeting pain-related conditions.

Drug Discovery & Development | 13/04/2026 | By News Bureau |  184

Artivion Secures US FDA Approval for Endospan's NEXUS Aortic Arch System

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that the US Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the NEXUS Aortic Arch System, developed by Endospan Ltd. (Endospan), Artivion's long-standing partner.

Drug Discovery & Development | 08/04/2026 | By Darshana |  174

Concept Medical Unveils Landmark SirPAD Trial at ACC 2026, Advancing PAD Treatment

Concept Medical Inc. (CMI), a global leader in drug-delivery technologies for vascular interventions, has announced the presentation of the world’s largest randomized controlled trial evaluating a sirolimus-coated balloon (SCB) for peripheral artery disease (PAD) at the ACC 2026 Scientific Sessions.

Drug Discovery & Development | 01/04/2026 | By Darshana |  287

Wockhardt's Zaynich Gets CDSCO SEC Nod for Gram-Negative Infections

CDSCO’s Subject Expert Committee (SEC) recommends Wockhardt’s Zaynich (Zidebactam/Cefepime) for Gram-negative infections, paving the way for DCGI approval of the novel antibiotic in India.

Drug Discovery & Development | 30/03/2026 | By News Bureau |  385

Takeda's Zasocitinib Shows Strong Skin Clearance in Psoriasis Study

Takeda reports Phase 3 data showing zasocitinib delivers rapid, durable skin clearance in psoriasis, with ~70 percent achieving sPGA 0/1 and early PASI 75 response, with a consistent safety profile.

Drug Discovery & Development | 30/03/2026 | By News Bureau |  241

PharmaJet, REDE-TB to Launch Clinical Study on Needle-Free TB Skin Testing Technology

The study will evaluate accuracy, safety and patient acceptance of needle-free Tropis system compared to traditional tuberculin skin test

Drug Discovery & Development | 26/03/2026 | By News Bureau |  142

LB Pharmaceuticals Starts Phase 3 Trial for LB-102 in Schizophrenia

LB Pharmaceuticals initiates Phase 3 NOVA-2 trial of LB-102 for schizophrenia, enrolling ~460 patients to assess PANSS score, symptoms and safety, with topline results expected in 2H 2027.

Drug Discovery & Development | 26/03/2026 | By News Bureau |  255

Dupixent Approval in Japan Boosts Biologics Manufacturing Demand for Sanofi and Regeneron

The Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization to Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP), a rare and debilitating skin disorder.

Drug Discovery & Development | 25/03/2026 | By Darshana |  210

Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer

Biotheryx advances BTX-9341 into a dose expansion trial with fulvestrant for HR+/HER2- breast cancer, aiming to overcome resistance in patients previously treated with CDK4/6 inhibitors.

Drug Discovery & Development | 19/03/2026 | By News Bureau |  174

US FDA Pushes Shift Away from Animal Testing in Early Drug Studies

The U.S. Food and Drug Administration (FDA) is pushing for a shift away from animal testing in early-stage drug development, encouraging companies to adopt more modern and human-relevant methods.

Drug Discovery & Development | 19/03/2026 | By Darshana |  167